New strategies, so-called 'omics' and informatics technologies that hold the promise to detect genetic and tissue-specific changes with increasing sensitivity are now becoming available for research into complex disease. These methods permit the simultaneous analysis of thousands of genes, genetic variants, proteins or metabolites. It is therefore now possible to detect and track global molecular changes-from the genetic (genomics) to the transcriptional, translational and post-translational expression levels (proteomics and metabolomics). Most importantly, apart from the advantage of global experimental scale, the technologies do not make assumptions about the role of molecules that affect blood pressure (BP), and as such have the potential to underpin unknown and unexpected but pathophysiologically important hypertension variants. This in turn should provide additional insight into BP regulation and help to identify potential diagnostic markers and targets for anti-hypertensive treatment.
High BP, or hypertension, is a major (worldwide) risk factor that leads to fatal cardiovascular diseases. 1, 2 Most cases of hypertension have unknown aetiology, and are thus classified as essential hypertension. Despite progress made towards understanding rare monogenic forms of hypertension, 3 the aetiology and pathogenesis of essential hypertension remain poorly understood. Genetically, BP is a continuous trait, and variation of BP across the population is attributed to the combined influence of multiple hereditary and environmental factors. 4, 5 This leads to the as yet unanswered question: can we find the 'hypertension' genes? The answer to this question, in our view, becomes central to our understanding of the aetiology of hypertension and may indeed lie in the methods used to discover these genes or proteins. Here, we briefly attempt to summarize the strategies used so far and discuss the possible future directions of hypertension 'omic' studies (Table 1) . For an overview of the genetics of hypertension in humans and the importance of the animal model, we refer the reader to the excellent review by Cowley. 6 
Studies based on DNA variations
Linkage-based genome-wide scans based on microsatellite markers The genome-wide scan (GWS) is best defined as a search for quantitative trait loci (QTL, chromosomal regions containing a gene or genes that may influence BP) across the entire genome using anonymous, highly polymorphic (and thus genetically informative) microsatellite markers in a cohort of biologically related subjects. GWS has been designed primarily to find regions linked to BP without making presumptions as to the physiological or pathological relevance of the genes in the region. Thus, the detected signals of linkage to BP are not biased by pre-experimental speculations, and the nominal probability of detecting linkage is similar across all chromosomal regions. Tens of genomic screens in search of regions linked to BP have been performed so far, and at least one BP quantitative trait locus has been found in each human chromosome. 6, 7 Examples of the genome-wide screen approach include the Family Blood Pressure Programme (FBPP) and the British Genetics of Hypertension (BRIGHT) study. 8, 9 The FBPP showed only suggestive linkage of the short segment on chromosome 1 to diastolic BP (DBP). 9 In contrast, the BRIGHT study showed that a locus on chromosome 6q attained genome-wide significant linkage to hypertension. In addition, three further loci on chromosomes 2q, 5q and 9q were linked (with suggestive evidence) to hypertension in the BRIGHT cohort. 8 However, an update on the study including the addition of new markers and families identified novel regions of interest on chromosomes 1q and 11q and diminished linkage of the previous regions. 10, 11 The use of different genetic markers, study designs and statistical methods complicate the interpretation of the GWS based on microsatellites. In addition, the caveat of multipoint linkage studies is that the rate of false-positive and false-negative 12 Only a few of these candidate regions have been successfully dissected in positional and functional studies leading to the identification of the gene(s) drivers of the detected signal. 13, 14 Thus, linkage-based genomic screens-although successful in providing evidence for heterogeneous, polygenic and population-specific background of essential hypertension-have made a relatively small contribution to the identification of the underlying pathophysiology of hypertension. A limited number of markers (usually a few hundred), arbitrary definitions of distances between markers that may inflate false-positive or negative results in multipoint analysis and the large size of the BPQTLs (millions of bps) have all contributed to the relative lack of success of this strategy in underpinning the hypertension genes.
Candidate gene approach based on single-nucleotide polymorphisms The candidate approach that examines associations between hypertension and single-nucleotide polymorphisms (SNPs) in pathophysiologically relevant genes has not been successful in identifying suitable candidate(s) for further verification in functional studies. Candidate genes have been selected for examination of their association with hypertension based on: (1) their physiological contribution to BP regulation; (2) their location within BP QTL implicated by GWS; (3) studies of Mendelian hypertensive syndromes; or (4) studies of genetic hypertensive rat and mouse models. 6 Hundreds of studies performed so far have produced overwhelmingly inconsistent results. 15, 16 Thus, despite high expectations, the contribution of most of the candidate association studies to the understanding of hypertension and its genetic determinants has been modest. One explanation for the lack of success of this strategy to dissect the genetic background of hypertension may be related to an incorrect a priori assumption that predisposition to hypertension is driven by genes encoding classical BP regulators such as angiotensinogen or endothelin-1. In fact, lessons learnt recently from studies on another complex disease-type 1 diabetes-suggest that truly causative, common, consistently associated variants may not have an obvious physiological relationship to the common disease. 17 Alternatively, a failure of this strategy may be related to a lack of robust phenotyping, hidden population stratification, lack of relative power, lack of consideration of linkage disequilibrium (LD) in the human genome and-perhaps most importantly-imprecise selection of genetic markers. Recently, uniform criteria have been suggested for association studies, 18 and this standardization of the study designs should have an impact on the quality of research in this area. However, it is the availability of genetic information in the public domain that will make a major contribution to the enhancement of this strategy to the identification of hypertension genes. Specifically, a catalogue of SNPs, where they occur in the DNA, and how they are distributed among people within populations and among populations in different parts of the world has been completed by the HapMap project (http://www.hapmap.org). The HapMap project enables scientists to genotype a lower number of SNPs by taking advantage of LD between them. LD is defined as the tendency of alleles located close to each other on the same chromosome to be inherited together more frequently than expected by chance. This means that many SNPs can be defined by the same single tag SNP (haplotype). It is therefore no surprise that with the advent of the HapMap project 19 complemented with cheaper and larger scale genotyping technologies, a new future awaits the study of the genetics of hypertension.
Genome-wide association (GWA) studies and hypertension: more genes with small effect? An important difference between linkage screens and genome-wide association studies is that the latter does not require DNA availability from related family members but can be conducted using unrelated cases and controls. The results of the two largest genome-wide association studies for hypertension have been published recently. The first is the Wellcome Trust Case Control Consortium in the United Kingdom, 20 and the second is the Framingham Heart Study 100K Project in the United States.
21 Surprisingly, in contrast to other common diseases that showed association with several loci of the human genome, association with hypertension was too modest to exceed the stringent criterion of statistical significance (this is described as the P-value threshold of 5 Â 10 À7 ). In addition, none of the variants previously implicated by candidate studies showed clear evidence for association, although a few, such as promoter of the WNK1 gene (WNK lysine-deficient protein kinase 1 gene), showed suggestive association with hypertension. Furthermore, data from a whole genome scan for type 2 diabetes in a Scandinavian cohort 22 available online (http://www.broad.mit.edu/diabetes/scandinavs/index.html) show no variants associated with hypertension. Suggestive association of three variants with DBP in this population has not been replicated in other cohorts. A number of possible explanations should be considered. First, hypertension may have fewer common risk alleles of larger effect sizes than other common diseases. If so, to identify susceptibility variants for hypertension, multiple larger scale studies are required. Second, the susceptibility variants may be poorly represented on the chip used for genotyping. Novel, additional genotyping platforms using increased density of markers and better genetic representation are under construction and will soon become commercially available. Third, hypertension may be more susceptible than other phenotypes to the diluting effects of misclassification bias due to the presence of latent hypertensive individuals within the control samples. 23 We anticipate that a number of GWA for hypertension will be published during the coming months and years. These studies are a significant outcome of the Human Genome and HapMap projects, and hopefully they will report novel and consistent variants of specific genes or narrow genomic regions that are associated with the presence of hypertension. Even though the results for the association studies are far from impressive, we still believe that the GWA will provide novel, unbiased information about the heritable basis of hypertension at a level of detail that has not been possible previously. It will also be aided by resequencing of entire genes or genomic regions in many subjects.
Controversial and unresolved issues in the search for hypertension genes How to solve the heterogeneity of essential hypertension? The heterogeneity of essential hypertension is one of the major contributors to the discordant findings from linkage and association studies on BP-related phenotypes. Indeed, different genetic variants may underlie upregulation/downregulation of a large number of BP regulatory pathways that manifest in a similar manner-as BP elevation. Thus, subjects with different genetic, molecular and sub-clinical background are classified as essentially hypertensive based only on the arbitrary definition of BP elevation. The most important strategy to dissect the heterogeneous nature of hypertension is a more precise phenotyping. Patients with essential hypertension represent a wide spectrum of clinical entities-from young men with early onset hypertension and over-activation of sympathetic nervous system to elderly women with metabolic syndrome. We propose that the classification criteria of hypertensive subjects should be more specific than BP values and should include other demographic, anthropometric, clinical and biochemical information. Only systematic evaluation of metabolic, vascular, cardiac and renal characteristics followed by appropriate classification of individuals with essential hypertension into different clinical categories will narrow down the phenotypic heterogeneity of hypertension, thus increasing the probability of capturing the causative genetic variants in linkage/association studies. The 'phenomics' strategy 24 has already been successful in the identification of several monogenic forms of hypertension/hypotension 25 and illustrates how the capture of certain phenotypic feature of BP elevation leads to the molecular dissection of the clinical syndrome that clusters in families.
How relevant is the common disease-common variant hypothesis to hypertension? There is an ongoing debate whether genetic predisposition to hypertension is mediated by common or rare variants. During the early years of hypertension genetics there was a general conformity that the majority of genetic contributions to BP variation are exerted by common rather than rare alleles. 26 Consequently, the majority of current studies on hypertension genetic use the specific criteria of 'commonness' of minor allele 1, 5 or 10%. 22, 27 Exclusion of SNPs with minor allele frequency below these cutoff thresholds may also reflect, at least to some extent, the financial constraints of genotyping the large number of subjects that are needed for properly powered genetic studies using rare alleles. Support for the rare allele-common variant hypothesis comes from recent data from Lifton's group and shows that rare variants in three genes involved in regulation of renal ion/water handling produce clinically significant BP reduction and protect from development of hypertension in the well-known Framingham study. 28 We believe that the answer to the above question is still unknown and we should not discount the associations already found between common alleles and hypertension. It is therefore likely that both common and rare variants are relevant to hypertension.
Evolutionary
genetics of blood pressure regulation. Evolutionary genetics is a very important source of information for studies on human hypertension. Comparative genomic belongs to one of the most commonly explored strategies of evolutionary genetics in hypertension at present. Comparative analysis of genes conserved on the syntenic (that is human-rat) QTL has made a major contribution to identification of novel variants of human hypertension.
14 Genetic variation within evolutionarily conserved sequences is a wellaccepted surrogate of molecular functionality and may be explored in silico using publicly available web-based interfaces. 29 and experimentally using various molecular methods such comparative hybridization. In addition, conservation of SNPs alleles among species is considered a marker of their functional relevance and may be modelled in silico, that is in SNP Function Annotation Portal. 30 It is anticipated that these strategies and tools will assist in the analyses of the findings generated by high-throughput genotyping studies and bring us closer to the full dissection of genetics of human hypertension.
Should we give up on hypertension as a phenotype and focus on intermediate phenotypes? Although there is merit in this suggestion, there is always the possibility that intermediate phenotypes could also be heterogeneous to some extent. However, intermediate phenotypes are likely to remain under tighter genetic control than the ultimate clinical manifestations of cardiovascular disease. Therefore, high-fidelity phenotyping and 'phenomics' strategy 24 will be essential in reducing the phenotypic heterogeneity of human hypertension and will make a major contribution to underpinning the genetic variants that regulate BP elevation. Similar precise phenotyping will be needed in pharmacogenetic studies. The novel candidates identified in these investigations will form a platform for further exploration of other molecules within the novel molecular signalling cascades.
Does the environment play a bigger role in hypertension? It is well accepted that environmental exposures accounts for approximately 70% of BP variation. 25 The remaining 30% is attributed to genetic influences. Although heritability estimates of BP vary (20-70%) it is unlikely that collective influences of genetic variants would make a more significant contribution to the pathogenesis of hypertension than environmental factors, at least at the population level. It is also becoming increasingly clear that very precise clinical information on environmental exposure other than standard data on alcohol consumption and smoking (that is factors such as stress, education, income, civil status, diet, air pollution and so on) will be absolutely essential in full dissection of gene-environment interactions. Yet, very few studies have access to precise characteristics on the environmental exposure. Therefore, future genetic investigations should focus on the full characteristics of the recruited subjects in terms of their exposure to the environment and examination of the patterns of gene environment interactions. 31 Should we concentrate on the genetic basis of hypertension complications and treatment response rather than those that cause dysregulation of BP? It is also worth considering whether the genetic background of hypertension complications and treatment response may be more traceable than the genes that cause dysregulation of BP. Although both complications and response to anti-hypertensive medication represent more definite phenotypes than BP elevation, their genetic control is much more complicated than that of BP elevation. Apart from genes that strictly regulate BP elevation, the hypertensive target organ damage is most likely influenced by additional genetic factors that are responsible exclusively for adaptive organ-independent response to hypertension. 32 Finally, genetic control is probably related to tissue-specific response to BP elevation and manifests only in the presence of factors permissive for either cardiac/renal or vascular damage.
Global DNA variation and hypertension
In addition to SNPs, copy number variations (CNVs) of genomic segments contribute considerably to the submicroscopic genomic diversity in humans. These CNVs include deletions, insertions and duplications larger than 1 kb and up to several Mb. 33 The enormous extent of this type of variation has recently been documented by Redon et al. 34 who established a genome-wide CNV map in humans. Surprisingly, 1447 regions of the human genome are characterized by CNVs (or 12% of the human genome). Nearly 3000 genes are associated with CNV. An example of this is the CNV that predisposes humans to increased kidney-related disease susceptibility, which includes low copy numbers of the FCGR3B gene associated with increased susceptibility to mediated glomerulonephritis. 35 Another example is polycystin, the gene responsible for autosomal-dominant polycystic kidney diseaseone of the most common monogenic human disorders. 36, 37 The question that is yet to be answered is whether CNVs contribute to hypertension. CNVs can already be detected by genome-wide association, so the answer to this question may also be revealed in the near future.
Studies based on RNA level variation
The next level of research involves the examination of difference in RNA levels between controls and cases. Recent advances have made it possible to examine the expression levels of virtually all genes (mRNA or proteins) simultaneously using microarrays. As the tools for gene expression profiling using microarrays have become more widely available, the number of investigators applying this technology in hypertension research-as in other fields of biomedical research-has grown rapidly, in particular those using animal models. In humans, microarrays obviously require functioning cells or tissues for analysis in both cases and controls. A direct application to the genetics of human hypertension requires samples from relevant tissues.
Such approaches are becoming technically feasible due to availability of tissue banks. The Silesian Renal Tissue Bank-a collection of renal tissues from Polish patients undergoing unilateral elective nephrectomy that has recently made a major contribution to detection of a new gene of human hypertension-is an excellent depository of biological material for microarray transcriptomics. 14 Ongoing research into the understanding of the human genome has shown that non-coding RNAs may have many more functions then predicted previously. 19 It seems that the original term 'junk DNA' given to non-coding RNA needs to be critically assessed in future genetic research into hypertension. Recent discoveries show that many of these non-coding sequences are indeed expressed in BPregulating tissues. As a result, the transcriptome (expressed sequences) may be far more complex than first considered. 38 Perhaps most riveting is the new class of small non-coding RNAs called microRNAs (miRNA). The function of these miRNA seems to be to inactivate specific mRNAs and deplete their corresponding proteins. The miRNAs average about 22-25 nucleotides in length and are transcribed from DNA as hairpin precursors. They can affect major processes such as development, apoptosis, cell proliferation, hematopoiesis and patterning of the nervous system. Several studies have shown that these miRNA may be involved in disease processes such as heart failure. 39 A recent study has shown that inhibition of miR-122, which is highly expressed in the liver, can reduce cholesterol levels in mice. 40 Thus, we need to identify the actions of miRNAs (if present) on BP regulation.
Studies based on protein level variation
It has become widely recognized that the genome represents only the first layer of complexity in unravelling normal and pathophysiological disease pathways. Proteins are the ultimate products of the human genome, and their number cannot be predicted from the genome sequence. It is estimated that there are up to 10 times as many distinct proteins as genes in humans, due to differential splicing and many post-translational protein modifications. 41 Many modifications in protein structure and function add complexity to that of the genome and represent what has become the protein equivalent of the genome; namely, the proteome. However, one has to take into account that the proteome is not only the complete protein complement expressed by a genome, but is also a highly dynamic entity that changes based on cellular state and extracellular milieu. Therefore, proteomics can be defined as the effort to establish the identities, quantities, structures, and biochemical and cellular function of all proteins in an organism, organ, or organelle, and how these properties vary in space, time and physiological state. 42 The currently available methods are changing rapidly. Conventionally, proteomic analysis has been accomplished by two-dimensional polyacrylamide gel electrophoresis. 43 Limitations of this technology are its reproducibility and lack of sensitivity and specificity. Thus, alternative methods such as liquid chromatography and more recently capillary electrophoresis (CE) have evolved.
The gel-free methods are usually faster, directly interfaceable with mass spectrometry and more amenable to automation. 44 CE coupled with mass spectrometry is a fast method with high resolution and, therefore, currently seems to be an ideal tool for clinical biomarker discovery and monitoring. Current data suggest that using multiple technologies dramatically increases the number of detected proteins, especially those present in the sample at very low abundance.
Challenges in the application of proteomics to cardiovascular disease begin with the selection of tissue samples. Several groups have reported on the application of proteomics techniques to analyse tissue or plaque specimens to study cardiovascular disease providing new insights into disease-related pathways. [45] [46] [47] [48] Several studies have focused on the analysis of body fluids derived through minimally invasive means. These studies were either based on pooled blood specimens, 49, 50 making individual sample classification impossible, or they included small patient cohorts without blinded studies for validation. Using 370 urine samples from 88 patients with severe critical coronary artery disease (CAD) and 282 controls, Zimmerli et al. 51 have been able to find a signature set of 15 urinary polypeptides that can identify CAD. Proteomics will not only offer the possibility of understanding normal and pathophysiological pathways hypertension but also has the potential to identify biomarkers for early diagnosis and as well as monitoring of therapeutic interventions. However, it is important to note that the highthroughput technologies involved in both RNA and protein studies still do not have robust validated data analytic methodologies. We need to be cautious before embarking into these experiments and interpreting the data meaningfully.
Studies based on molecular pathways and gene networks
The pathwayomic, or systems biology, approach investigates the network of molecules interacting within one BP regulatory system such as reninangiotensin-aldosterone system or b2-adrenergic signalling cascade. As the majority of biologically relevant molecular effects on BP are likely to arise from interactions within the same regulatory network, it is only logical that simultaneous investigation of the entire system may provide better insight into pathophysiology of hypertension than in-depth studies of single targets. The pathwayomic approach is also justified by clinical observation: elevated BP seen in the clinic is frequently, at least in early stages of hypertension, related to upregulation/ downregulation of one regulatory mechanism such as increased sympathetic drive. 52 Molecular pathways of hypertension can be investigated at the DNA, mRNA and/or protein level, making use of the approaches discussed in the previous sections.
The availability of tools that integrate current knowledge of systems biology permits investigators to define precisely the targets within the candidate regulatory network. 53 In addition, it is now possible to examine novel, sometimes unexpected, interactions between candidate molecules in silico (on the computer screen). Finally, gene-annotation repositories are becoming a new and important analytical tool for genome-wide association studies of complex diseases. We anticipate that availability of these resources and strategies and their experimental validation will facilitate identification of novel pathways and the further dissection of classical pathways of BP regulation. This will aid in identification of novel targets for anti-hypertensive drug discovery and potential diagnostic markers.
Closing remarks and perspectives
It may seem to non-molecular biologists or geneticists that the search for hypertension genes has taken longer than predicted, and more importantly the question may be asked: why should we bother if these effects are so small? First, technology is currently moving very fast, and we predict that the availability of many new resources-in particular, the human genome, better understanding of environmental contribution and new 'omic' technologies-is changing our basic understanding so deeply that we are bound to gain the benefits sooner or later. Second, the identification of statistically robust associations between genes/causative factors and hypertension even at very small odds ratios are likely to reveal new disease mechanisms. 54 Finally, although the full heterogeneous nature of essential hypertension is unlikely to be dissected for some time, and as pointed out by Loscalzo, 55 there is 'hyperbole, used to extol the importance of genomics', we now have an unprecedented chance to increase our understanding of the complex nature of hypertension and, furthermore, to relay this for clinical and public health benefits.
